Second-trimester prenatal screening for trisomy 21 using biochemical markers: A 7-year experience in one cytogenetic laboratory

Prenatal Diagnosis

Volumn 26, Issue 4, 2006, Pages 308-312

  Marical, Hélène ^a   Douet Guilbert, Nathalie ^a,b   Bages, Karine ^a   Collet, Michel ^a   Le Bris, Marie Josée ^a   Morel, Frédéric ^a,b   De Braekeleer, Marc ^a,b  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Chromosomal abnormalities; Maternal serum screening; Prenatal screening; Trisomy 21

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; KARYOTYPING; LABORATORY TEST; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; TRISOMY 21; ULTRASOUND;

ADULT; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DOWN SYNDROME; FEMALE; HUMANS; KARYOTYPING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 33646051217     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1398     Document Type: Article

References (27)

1. Audibert F, Dommergues M, Benattar C, Taieb J, Champagne C, Frydman R. 2001. Dépistage de la trisomie 21: clarté nucale et/ou marqueurs sériques?. Gynécol Obstét Fertil 29: 599-604.
2. Benn PA, Horne D, Briganti S, Greenstein RM. 1995. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome. Am J Obstet Gynecol 173: 496-501.
3. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
4. Burton BK, Prins GS, Verp MS. 1993. A prospective trial of prenatal screening for Down syndrome by means of maternal serum?-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol 169: 526-530.
5. Caron L, Tihy F, Dallaire L. 1999. Frequencies of chromosomal abnormalities at amniocentesis: over 20 years of cytogenetic analyses in one laboratory. Am J Med Genet 82: 149-154.
6. Chao AS, Chung CL, Wu CD, et al. 1999. Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotrophin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. Acta Obstet Gynecol Scand 78: 393-397.
7. Cheng EY, Luthy DA, Zebelman AM, Willimans MA, Lieppman RE, Hickok DE. 1993. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, HCG, and unconjugated estriol. Obstet Gynecol 81: 972-977.
8. Haddow JE, Palomaki GE, Knight GJ, et al. 1992. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 327: 588-593.
9. ISCN. 1995. An International System for Human Cytogenetic Nomenclature. S. Karger: Basel.
10. Kadir RA, Economides DL. 1997. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 9: 244-247.
11. Michailidis GD, Spencer K, Economides DL. 2001. The use of nuchal translucency measurement and second trimester biochemical markers in screening for down's syndrome. Br J Obstet Gynaecol 108: 1047-1052.
12. Muller F, Forestier F, Dingeon B, for the ABA Study Group. 2002. Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854 902 patients. Prenat Diagn 22: 925-929.
13. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. 2003. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 23: 833-836.
14. Nicolaides KH. 2003. Screening for chromosomal defects. Ultrasound Obstet Gynecol 21: 313-321.
15. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
16. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. 1992. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 80: 353-358.
17. Platt LD, Greene N, Johnson A, et al., for the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2004. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 104: 661-666.
18. Ryall RG, Callen D, Cocciolone R, et al. 2001. Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screening. Prenat Diagn 21: 553-557.
19. Sack GH, Alpern M, Webster T, et al. 1993. Chromosomal rearrangement segregating with adrenoleukodystrophy: A molecular analysis. Proc Natl Acad Sci U S A 90: 9489-9493.
20. Sheridan E, Williams J, Caine A, Morgan R, Mason G, Mueller RF. 1997. Counselling implications of chromosomal abnormalities other than trisomy 21 detected through a maternal serum screening programme. Br J Obstet Gynaecol 104: 42-45.
21. Spencer K. 1999. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free hCG: a seven year review. Br J Obstet Gynaecol 106: 1287-1293.
22. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110: 281-286.
23. Thilaganathan B, Slack A, Wathen NC. 1997. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 10: 261-264.
24. Van Dyke DL, Weiss L, Robertson JR, Babu VR. 1983. The frequency and mutation rate of balanced autosomal rearrangements in man estimated from prenatal genetic studies for advanced maternal age. Am J Hum Genet 35: 301-308.
25. Wald NJ, Watt HC, Hackshaw AK. 1999. Integrated screening for Down's syndrome based on tests performed during the first and second trimester. N Engl J Med 341: 461-467.
26. Wapner R, Thom E, Leigh Simpson J et al., for the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
27. Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP. 1993. Evaluation of multiple-marker screening for Down syndrome in a statewide population. Am J Obstet Gynecol 169: 793-797.